Methylfenidaat Retard Eg (Methylphenidate Hydrochloride)

Methylphenidate blocks the reuptake of dopamine and norepinephrine, increasing their levels at synaptic junctions. This heightened neurotransmitter activity enhances signaling in brain pathways that control attention, impulse control, and wakefulness, producing the therapeutic benefits seen in ADHD and narcolepsy.

The specific dose of Methylfenidaat Retard Eg is determined by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and response to therapy. Only a qualified healthcare professional should set the dosing regimen.

Safety data for methylphenidate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified prescriber after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methylfenidaat Retard Eg belongs to the psychostimulant class, similar to amphetamine‑based products. Compared with non‑stimulant options, it generally has a faster onset of action and may be more effective for core ADHD symptoms, but it also carries a higher potential for cardiovascular and psychiatric side effects, requiring careful monitoring.

Methylfenidaat Retard Eg should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

The medication is taken orally, usually as a whole tablet or capsule, with or without food as directed by the prescriber. Swallow the dose whole; do not crush, chew, or split extended‑release forms unless specifically instructed by a healthcare professional.

Serious risks include cardiovascular events such as hypertension, arrhythmia, or chest pain; psychiatric effects like new or worsening psychosis; severe allergic reactions; and rare but significant growth suppression in children. Patients should be monitored regularly for these potential complications.

Methylfenidaat Retard Eg is contraindicated in individuals with known hypersensitivity to methylphenidate, those taking monoamine oxidase inhibitors, patients with severe cardiovascular disease, uncontrolled hypertension, or a history of psychosis. It should also be avoided in patients with a documented history of substance misuse.